Methods
ype 2 diabetes mellitus is associated with an increased risk of cardiovascular disease. 1 In particular, diabetic patients have a higher incidence of congestive heart failure compared with age-matched non-diabetic subjects. 2 Although left ventricular (LV) systolic dysfunction occurs only infrequently, diastolic dysfunction is a commonly observed cardiovascular manifestation even in the absence of ischemic or hypertensive heart diseases in diabetic patients. 3, 4 The pathogenesis of LV diastolic dysfunction is not fully clarified in the diabetic heart, but myocardial fibrosis is one of the most important mechanisms for the diastolic dysfunction. [5] [6] [7] Activation of the local reninangiotensin system is likely to contribute to the development of myocardial fibrosis because its importance has been demonstrated in a number of animal models of LV diastolic dysfunction. 8, 9 The renin-angiotensin system is certainly upregulated in the diabetic myocardium, 10 and locally produced angiotensin II might well facilitate the myocardial fibrosis. 11 Thus, we might expect angiotensin II type 1A receptor blockade (ARB) working towards cardioprotection by reducing myocardial fibrosis in diabetic patients.
Myocardial fibrosis has been only assessable via the histological examination of the myocardial specimen; however, this requires biopsy and should not be justified from the ethical view in most of the diabetic patients. Most recently, the use of serological markers of collagen turnover was shown to provide estimates of collagen types I and III turnover, that is, production and degradation, for the noninvasive monitoring of myocardial fibrosis. [12] [13] In contrast, LV diastolic filling is non-invasively assessable by analyzing pulsed Doppler mitral flow velocity patterns. Even LV chamber stiffness (KLV) may be assessed from the measurement of the deceleration time of the early diastolic mitral filling wave. 14 Thus, we repeatedly assessed collagen turnover and LV diastolic filling in diabetic patients to test the hypothesis that chronic ARB alters myocardial collagen turnover leading to an improvement of diastolic dysfunction in diabetic patients. sion (systolic blood pressure of 160 mmHg or greater), heart diseases or renal diseases and were among those regularly followed in the outpatient clinic of Osaka Police Hospital. Prior to the study, they were referred for an echocardiography laboratory to examine LV function, and only those with abnormal LV diastolic dysfunction but with normal LV systolic function were selected. None of the patients with ischemic ECG changes (≥0.1 mV, horizontal S-T shift) were detected in the Master's 2-step exercise test. The criterium for LV diastolic dysfunction was a mitral E/A ratio of less than 0.8 or greater than 1.5. None showed a mitral E/A ratio greater than 1.5, and consequently only those with a mitral E/A ratio of less than 0.8 were selected. LV systolic function was judged normal if an ejection fraction was 50% or greater. A total of 48 patients met the criteria (35 men and 13 women, mean age 67 years). The 48 patients were randomly divided into 1 of the 2 subsets: 1, administering candesartan cilexetil for 6 months (ARB group), and 2, administering no medicines affecting the renin angiotensin system such as angiotensin-II receptor blocker, angiotensin-converting enzyme inhibitor or spironolactone (control group). Hypertension was treated by the administration of blockers or calcium channel blockers in any of the control group patients if necessary. The ARB group consisted of 38 patients with type 2 diabetes mellitus (27 men and 11 women; mean age 66 years). The other 10 patients (8 men and 2 women; mean age 67 years) belonged to the control group. All subjects gave informed consent, and the local committee on human research approved the study protocol. Candesartan cilexetil, was administered 8 or 12 mg/day for 6 months in all of the patients of the ARB group; none of the patients received antihypertensive agents except candesartan cilexetil. All patients received sulfonylurea agents. Medication did not change during the observation term. Biochemical, hemodynamic and echo parameters were obtained at entry and repeated after 6 months. None of the patients presented any condition causing alterations to the serum level of carboxy-terminal propeptide of procollagen type I (PIP) or carboxy-terminal telopeptide of collagen type I (CITP) (alcoholic liver disease, metabolic bone disease, hyperthyroidism, renal insufficiency).
Biochemical Determinations
PIP, an index of collagen type I synthesis, and CITP, an index of collagen type I degradation were determined by radioimmunoassay according to a method previously de-scribed. 15 The PIP/CITP ratio was used as an index of coupling between the synthesis and degradation of collagen type I. Procollagen type III amino peptide (PIIIP), as an index of synthesis of collagen type III, was also determined by radioimmunoassay. Biochemical parameters such as plasma B-type natriuretic peptide (BNP) level were measured by using routine laboratory methods. The N-telopeptide-tohelix pyridinoline cross-linking site in type I collagen (NTX) was determined using obtained urine according to a method previously described. 16 
Echocardiographic Study
Two-dimensional (D) echo targeted M-mode and Doppler recordings were obtained in each patient as previously described. 15 The LV mass index was calculated by dividing the LV mass by body surface area. 17 Pulsed Doppler mitral flow velocity pattern was recorded at the mitral tip by 2-D echo guidance to provide measurements for quantitative analysis. In addition to the ratio of the peak early diastolic filling velocity to the peak velocity at atrial contraction (E/A ratio), the deceleration time (TDEC) of the early diastolic filling wave was measured to estimate the LV stiffness constant (KLV) according to the following equation. 14 KLV = (0.08:TDEC) 2 (mmHg/ml)
Statistical Analysis
Results are expressed as mean±SD. Data were analyzed using statistical software (STATVIEW II, Abacus Concepatients, Berkeley, CA, USA). Comparisons between the 2 groups were analyzed by using the unpaired Student's t-test. Differences between data before and after ARB were assessed by using the paired Student's t-test. Simple linear regression analysis was used to examine the relationship of ARBinduced changes in the LV chamber stiffness constant and associated changes in collagen type I turnover. Correlation coefficients were calculated by linear regression analysis. A p value of less than 0.05 was considered statistically significant.
Results

Patient Characteristics
There were no significant differences in any parameters at baseline between the ARB and control groups (Table 1) . Hypertension was present in 45% of the ARB group and 40% of the control group. All patients had only mild hypertension, with systolic blood pressure ranging from 140 to 160 mmHg. Table 2 shows changes in the degree of diabetes mellitus following chronic ARB. Neither the glucose level nor the hemoglobin (Hb) A1c level changed after ARB over a 6-month period.
Effects of Chronic ARB on Hemodynamics, Echocardiographic Parameters and Plasma BNP Level
The mean value of systolic blood pressure fell slightly following chronic ARB, but the change was minimal. There was no change in diastolic blood pressure. LV ejection fraction slightly increased following ARB, which probably reflected the slight decrease in systolic blood pressure. ARB did not affect the LV mass index. The mitral E/A ratio increased from 0.65±0.11 to 0.75±0.19 (p<0.01) following 
Data are mean ± SD. *p<0.05, **p<0.01. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; E/A ratio, ratio of the peak early diastolic filling velocity to the peak velocity at atrial contractinon; LAD, left atrial dimension; LVDd, left ventricular diastolic dimension; EF, ejection fraction; FS, fractional shortening; LVMI, left ventricular mass index; KLV, left ventricular stiffness constant; TDEC, the deceleration time of the early diastolic filling wave. Other abbreviation see in Table 1 . Table 1 . chronic ARB. The mean value of the mitral deceleration time (TDEC) or KLV did not change following ARB. In contrast, there was no significant change in any hemodynamic or echocardiographic parameter in the control group (Table 3) . The plasma BNP concentration slightly decreased following chronic ARB, but the difference did not reach the statistical significance ( Table 2) .
Effects of Chronic ARB on Collagen Turnover
There was no significant change in any index of collagen turnover in the control group (Table 4 ). In contrast, PIP decreased (p<0.05), and CITP increased (p<0.01) following chronic ARB. Consequently, the PIP/CITP ratio, an index of coupling between the synthesis and degradation of collagen type I, decreased from 31±13 to 26±10 (p<0.01). Serum PIIIP concentration was not high even at baseline, and there was no significant change following chronic ARB. The NTX also did not change following chronic ARB ( Table 4 ). The changes in the indexes of collagen turnover following chronic ARB were compared with the associated change in KLV to see which of collagen production, degradation or both affected the ARB-induced change in the LV chamber stiffness constant in the diabetic hearts (Fig 1) . The change in the PIP/CITP ratio correlated with the change in KLV (r=0.39, p<0.05), indicating that the LV chamber became more compliant in the hearts that had accelerated collagen turnover. The change in PIP did not correlate with the change in KLV (r=0.08, p=NS). In contrast, the changes in CITP correlated with the change in KLV (r=0.35, p<0.05), indicating that the LV chamber became more compliant in the hearts that had accelerated collagen degradation.
Discussion
The present study represents the first clinical trial that has assessed the effect of chronic ARB on LV diastolic dysfunction in patients with type 2 diabetes and who do not have major cardiovascular disorders. The main findings of this study are summarized as follows: (1) ARB for 6 months was associated with an improvement of LV diastolic filling in type 2 diabetic patients with LV diastolic dysfunction;
(2) ARB for 6 months was associated with the alteration of collagen type I turnover in type 2 diabetic patients with LV diastolic dysfunction; and (3) there was an association between ARB-induced changes in the LV chamber stiffness constant and the associated changes in collagen type I turnover, particularly those of collagen type I degradation.
LV function
The LV diastolic dysfunction is detectable in diabetic patients even without diabetic complication or cardiovascular disease, suggesting that LV diastolic dysfunction can act as early functional evidence of a specific diabetic cardiomyopathy. 18 Reported abnormalities in LV diastolic function included a prolonged isovolumic relaxation period, delayed mitral valve opening and decreased early diastolic filling, increased atrial contribution of the LV filling, reduced mitral E/A ratio, etc. In the present study, all of the diabetic patients with LV diastolic dysfunction we selected had a reduced mitral E/A ratio. Diabetes mellitus alone might be an unlikely cause of severe LV diastolic dysfunction, resulting in a pseudonormalized to restrictive mitral flow velocity pattern. Chronic ARB increased the mitral E/A ratio in our patients. An increase in the mitral E/A ratio does not necessarily mean an improvement in LV diastolic performance 19 ; however, this is not the case in our data of the mitral E/A ratio. There were slight increases in the LV ejection fraction and fractional shortening systolic function, which is probably reflective of a decrease in systolic blood pressure; thus, LV diastolic function was considered the only LV performance that ARB affected. It is known that the increase in plasma BNP is not remarkable in patients with LV mild to moderate diastolic dysfunction as compared with those with LV systolic dysfunction. 20 The lack of change in plasma BNP concentration following chronic ARB in our patients might be explained by this.
Collagen Turnover
In a previous animal study, candesartan treatment significantly improved diastolic dysfunction through attenuated myocardial fibrosis. 21 The ARB-induced improvement in LV diastolic filling was associated with a decrease in the index of collagen production and with an increase in the index of collagen degradation. The data indicate that ARB works on collagen turnover more towards degradation than towards production, leading to the decrease in myocardial fibrosis and hence the improvement in LV diastolic filling. More interestingly, there was a correlation between the change in the ARB-induced PIP/CITP ratio and the associated change in the LV chamber stiffness constant, KLV. The change in KLV correlated with the change in CITP but not with the change in PIP, suggesting that the improvement of the LV chamber stiffness constant might be attributed more to the enhanced collagen degradation than to the decreased collagen synthesis. However, there were no significant changes in KLV following chronic ARB. Although KLV is a good estimate of LV stiffness, it might well be affected by LV relaxation. Specifically, the shortening of LV relaxation is likely to shorten mitral deceleration time and hence increase KLV. This might be a reason for the constant KLV in spite of the increases in the E and E/A ratio following chronic ARB in our patients. In contrast, the change in the E and E/A ratio did not correlate with the change in CITP (r=0.179; p=0.29; r=0.027, p=0.87, respectively). This might be at least partially explained by the fact that the E and/or E/A ratio reflected LV relaxation rather than the stiffness constant. In a previous study, long-term ARB with losartan resulted in the reduction of myocardial fibrosis and decreases in both PIP and KLV in the hypertensives, with LV hypertrophy and severe myocardial fibrosis at baseline. 22 The difference in the results of KLV between that study and the present study might be explained by the difference in the underlying disease accounting for myocardial fibrosis and LV diastolic dysfunction. NTX did not change following long-term ARB despite the enhanced collagen degradation. The degradation might not have involved the cross-linking site in type I collagen.
Diabetes Mellitus and Hypertension
There are many papers that indicate the presence of abnormal collagen turnover in subjects with hypertensive heart disease. 11, 13, 15, 23 The abnormal collagen turnover is certainly reversed by ARB not only in animals but also in patients with hypertension. 11, 15 Therefore, we analyzed our data to see whether there was a difference in any result between patients with and without associated hypertension. There were no differences between those with and without hypertension. However, there are no doubts that the association of these, if untreated, synergistically accelerates the development of LV dysfunction. In hypertension, reactive Circulation Journal Vol.71, April 2007 or reparative myocardial fibrosis is a result of increased collagen type I and type III synthesis by fibroblasts and of unchanged or decreased extracellular collagen degradation. 24 The effects of ARB on myocardial fibrosis were shown more through the decreased production than through the increased degradation in hypertensive patients. 11 Our data from diabetic patients were somewhat different because ARB-induced change in the LV stiffness constant was related to the augmented collagen degradation rather than to the decreased collagen production. Thus, ARB works to improve myocardial fibrosis and hence LV diastolic dysfunction both in diabetes mellitus and hypertension patients, but the mechanism is perhaps likely be, at least partially, different from each other. Chronic ARB results in the reversal of LV hypertrophy, which is in addition to improved relative wall thickness in hypertensive subjects. 25 None of our patients had LV hypertrophy even at baseline, and this might account for the lack of change in the LV mass index in our patients.
Diabetes Control
The relationship between LV diastolic dysfunction and glycemic control in diabetic patients is still a matter of debate. Previous animal studies have shown that myocardial contraction and relaxation are impaired in diabetic animals, and that these are reversible with biochemical changes after adequate insulin therapy. 26 In fact, the degree of reversibility is closely related to the dose of insulin used in these studies. On the contrary, other studies have shown that improvement in glycemic control was not associated with changes in LV diastolic function. 27 In the present study, treatment of diabetes mellitus was unchanged during the observation period for any patient. Because plasma glucose or HbA1c level did not change in any of our patients, we did not comment on the impact of glycemic control in our results. The plasma glucose or HbA1c level did not change following ARB for 6 months. In other words, ARB did not improve or worsen the degree diabetes mellitus. The results of recent mega trials clearly showed that ARB reduces the risk of diabetes mellitus development. 28 However, our data suggest that ARB does not affect already diagnosed diabetes mellitus by itself. This result indicates that improvement of LV diastolic filling seem to be caused by ARB, not diabetes control.
Study Limitations
Some limitations of the present study are noted. First, myocardial biopsies were not performed in the present study. Both PIP and CITP were determined from the antecubital vein serum sample and were used as indexes of collagen turnover. It remains speculative about how much of the 2 peptides are of cardiac origin; other extra-cardiac sources should be considered. For example, a recent biological study disclosed that PICP in serum originates mainly from bone matrix turnover. 29 These serum markers might be also possibly reflect fibrosis of other organs associated with diabetes mellitus. Second, one might think the ARB-induced results are at least partially caused by the depressor effect of ARB. Thus, we analyzed whether the data are different between those patients who had their blood pressure decreased by 5 mmHg or greater and those without a change in their blood pressure. The result of diastolic filling or collagen turnover was not different between the subsets, and we might consider that the contribution of the depressor effect to our results was minimal. Finally, only a small number of patients were studied in the present study; therefore, the results need to be confirmed by a randomized trial with a larger population.
Conclusions
The chronic blockade of angiotensin II-mediated signaling pathway improves LV diastolic dysfunction in diabetic patients, at least partially through the attenuation of myocardial fibrosis by regulating collagen turnover. The present study strongly implies that long-term ARB might be useful in diabetic patients to reverse LV diastolic dysfunction, even in the absence of major cardiovascular complications such as hypertension, LV hypertrophy and ischemic heart diseases. Because the persistence of LV diastolic dysfunction in diabetic patients is likely to lead to a transition to heart failure, particularly diastolic heart failure, the longterm administration of angiotensin II type 1A receptor blockers might be effective in preventing heart failure. A future randomized trial might be necessary to see whether this leads to an improved disease prognosis.
